(MDVN) (MDVN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$81.44▼$81.4450-Day Range N/A52-Week Range$26.41▼$81.48VolumeN/AAverage Volume3.55 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A About (MDVN) Stock (NASDAQ:MDVN)Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.Read More MDVN Stock News HeadlinesSeptember 2, 2023 | thestreet.comMedivation Alzheimer's Drug Fails Pivotal StudyJune 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. June 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutJune 13, 2023 | morningstar.comCore Medalist ETFsMay 31, 2023 | bbc.co.ukThe Connor Phillips ShowApril 21, 2023 | thestreet.comIncyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation DealApril 21, 2023 | thestreet.comMedivation Stock Hits New 52-Week High (MDVN)December 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. April 1, 2023 | msn.comMavs Lose to Heat, Play-In Hopes Continue to Take Major HitsMarch 8, 2023 | msn.comMillie Bobby Brown is 'ready to leave Stranger ThingsJanuary 26, 2023 | msn.comLake Nacogdoches notches its first 2023 Legacy ShareLunkerJanuary 15, 2023 | msn.comEx-Huddersfield Town boss Danny Cowley pens emotional goodbye message to Portsmouth supportersDecember 29, 2022 | msn.comGoody’s Name Creates Another Addams Family Wednesday MysteryDecember 25, 2022 | thestreet.comMedivation (MDVN) Stock Surges, Will Explore SaleOctober 18, 2022 | finance.yahoo.comJupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives - Yahoo FinanceOctober 10, 2022 | msn.comNBC played the 'That’s So Raven' theme and people are freaking out about it: Best memes & tweetsOctober 7, 2022 | marketscreener.comPortage Biotech : NOTICE OF ANNUAL GENERAL MEETING - Form 6-K - Marketscreener.comAugust 5, 2022 | msn.comThe Impressions star Sam Gooden dies aged 87July 16, 2022 | thestreet.comCramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRNMay 31, 2022 | thestreet.comThe 5 Dumbest Things on Wall Street This Week: Aug. 3March 24, 2022 | benzinga.comOption Alert: MDVN 4,950 Jul $65 Call @Bid @$0.30 - Benzinga - BenzingaFebruary 7, 2022 | thestreet.com2 Longs and 2 Shorts to Watch in the Stock MarketApril 12, 2021 | benzinga.comDisclosure Insight Maintains High Risk Rating on Medivation - BenzingaOctober 22, 2020 | wsj.comInvestors Pump Billions into Biotech Startups, Pay Skyrocketing Prices - The Wall Street JournalOctober 21, 2020 | gurufocus.comNuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development - GuruFocus.comOctober 13, 2020 | prnewswire.comNuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas - PRNewswireSee More Headlines Receive MDVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today12/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:MDVN CUSIP58501N10 CIK1011835 Webwww.medivation.com Phone+1-415-5433470FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report MDVN Stock Analysis - Frequently Asked Questions How were (MDVN)'s earnings last quarter? (MDVN) (NASDAQ:MDVN) released its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analyst estimates of $214.52 million. The firm's quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.58 EPS. What other stocks do shareholders of (MDVN) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and This page (NASDAQ:MDVN) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (MDVN) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.